| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.044 | 0.4 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.12 | 0.4 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.038 | 0.4 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | 0.15 | 0.4 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |